Selection of Diverse Strains to Assess Broad Coverage of the Bivalent FHbp Meningococcal B Vaccine

Overview

Journal NPJ Vaccines

Date 2020 Feb 7

PMID 32025339

Citations 4

Authors

Shannon L Harris

Cuiwen Tan

John Perez

David Radley

Kathrin U Jansen

Annaliesa S Anderson

Thomas R Jones

Affiliations

Soon will be listed here.

Abstract

MenB-FHbp is a recombinant meningococcal serogroup B (MenB) vaccine composed of 2 factor H binding proteins (FHbps). Meningococcal vaccines targeting polysaccharide serogroup A, C, Y, and W capsules were licensed upon confirmation of bactericidal antibody induction after initial efficacy studies with serogroup A and C vaccines. Unlike meningococcal polysaccharide vaccines, wherein single strains demonstrated bactericidal antibodies per serogroup for each vaccine, MenB-FHbp required a more robust approach to demonstrate that bactericidal antibody induction could kill strains with diverse FHbp sequences. Serum bactericidal assays using human complement were developed for 14 MenB strains, representing breadth of meningococcal FHbp diversity of ~80% of circulating MenB strains. This work represents an innovative approach to license a non-toxin protein vaccine with 2 antigens representing a single virulence factor by an immune correlate, and uniquely demonstrates that such a vaccine provides coverage across bacterial strains by inducing broadly protective antibodies.

Citing Articles

Exploring the sequence diversity and surface expression of Factor H-Binding Protein among invasive serogroup B meningococcal strains from selected European countries.

Clark S, Willerton L, Claus H, Carannante A, Stefanelli P, Abad R Hum Vaccin Immunother. 2024; 20(1):2427471.

PMID: 39536321 PMC: 11562907. DOI: 10.1080/21645515.2024.2427471.

Serum bactericidal activity against circulating and reference strains of meningococcal serogroup B in the United States: A review of the strain coverage of meningococcal serogroup B (MenB) vaccines in adolescents and young adults.

Presa J, Burman C, Tort M, Cane A, Bocchini Jr J Hum Vaccin Immunother. 2023; 19(1):2212570.

PMID: 37257838 PMC: 10234135. DOI: 10.1080/21645515.2023.2212570.

Genetic Features of a Representative Panel of 110 Meningococcal B Isolates to Assess the Efficacy of Meningococcal B Vaccines.

Muzzi A, Bodini M, Topaz N, Masignani V, Vadivelu K, Marjuki H mSphere. 2022; 7(5):e0038522.

PMID: 36129279 PMC: 9599336. DOI: 10.1128/msphere.00385-22.

Broad vaccine protection against Neisseria meningitidis using factor H binding protein.

Findlow J, Bayliss C, Beernink P, Borrow R, Liberator P, Balmer P Vaccine. 2020; 38(49):7716-7727.

PMID: 32878710 PMC: 8082720. DOI: 10.1016/j.vaccine.2020.08.031.

References

Milagres L, Gorla M, Sacchi C, Rodrigues M . Specificity of bactericidal antibody response to serogroup B meningococcal strains in Brazilian children after immunization with an outer membrane vaccine. Infect Immun. 1998; 66(10):4755-61. PMC: 108586. DOI: 10.1128/IAI.66.10.4755-4761.1998. View

Holst J, Feiring B, Fuglesang J, Hoiby E, Nokleby H, Aaberge I . Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease. Vaccine. 2003; 21(7-8):734-7. DOI: 10.1016/s0264-410x(02)00591-1. View

Christodoulides M, Heckels J . Novel approaches to Neisseria meningitidis vaccine design. Pathog Dis. 2017; 75(3). DOI: 10.1093/femspd/ftx033. View

Cohn A, MacNeil J, Harrison L, Hatcher C, Theodore J, Schmidt M . Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease. Clin Infect Dis. 2009; 50(2):184-91. DOI: 10.1086/649209. View

Ostergaard L, Vesikari T, Absalon J, Beeslaar J, Ward B, Senders S . A Bivalent Meningococcal B Vaccine in Adolescents and Young Adults. N Engl J Med. 2017; 377(24):2349-2362. DOI: 10.1056/NEJMoa1614474. View

Stefanelli P, Neri A, Vacca P, Picicco D, Daprai L, Mainardi G . Meningococci of Serogroup X Clonal Complex 181 in Refugee Camps, Italy. Emerg Infect Dis. 2017; 23(5):870-872. PMC: 5403042. DOI: 10.3201/eid2305.161713. View

Read R . Neisseria meningitidis; clones, carriage, and disease. Clin Microbiol Infect. 2014; 20(5):391-5. DOI: 10.1111/1469-0691.12647. View

Stephens D, Greenwood B, Brandtzaeg P . Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet. 2007; 369(9580):2196-2210. DOI: 10.1016/S0140-6736(07)61016-2. View

Richmond P, Marshall H, Nissen M, Jiang Q, Jansen K, Garces-Sanchez M . Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis. 2012; 12(8):597-607. DOI: 10.1016/S1473-3099(12)70087-7. View

10.

Vernikos G, Medini D . Bexsero® chronicle. Pathog Glob Health. 2014; 108(7):305-16. PMC: 4241781. DOI: 10.1179/2047773214Y.0000000162. View

11.

Sierra G, Campa H, Varcacel N, Garcia I, Izquierdo P, Sotolongo P . Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann. 1991; 14(2):195-207; discussion 208-10. View

12.

Donald R, Hawkins J, Hao L, Liberator P, Jones T, Harris S . Meningococcal serogroup B vaccines: Estimating breadth of coverage. Hum Vaccin Immunother. 2016; 13(2):255-265. PMC: 5328210. DOI: 10.1080/21645515.2017.1264750. View

13.

Richmond P, Nissen M, Marshall H, Lambert S, Roberton D, Gruber W . A bivalent Neisseria meningitidis recombinant lipidated factor H binding protein vaccine in young adults: results of a randomised, controlled, dose-escalation phase 1 trial. Vaccine. 2012; 30(43):6163-74. DOI: 10.1016/j.vaccine.2012.07.065. View

14.

Donnelly J, Medini D, Boccadifuoco G, Biolchi A, Ward J, Frasch C . Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci U S A. 2010; 107(45):19490-5. PMC: 2984153. DOI: 10.1073/pnas.1013758107. View

15.

Taha M, Hawkins J, Liberator P, Deghmane A, Andrew L, Hao L . Bactericidal activity of sera from adolescents vaccinated with bivalent rLP2086 against meningococcal serogroup B outbreak strains from France. Vaccine. 2017; 35(11):1530-1537. DOI: 10.1016/j.vaccine.2017.01.066. View

16.

Masignani V, Comanducci M, Giuliani M, Bambini S, Adu-Bobie J, Arico B . Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J Exp Med. 2003; 197(6):789-99. PMC: 2193853. DOI: 10.1084/jem.20021911. View

17.

Thompson M, Ninis N, Perera R, Mayon-White R, Phillips C, Bailey L . Clinical recognition of meningococcal disease in children and adolescents. Lancet. 2006; 367(9508):397-403. DOI: 10.1016/S0140-6736(06)67932-4. View

18.

Hoiseth S, Murphy E, Andrew L, Vogel U, Frosch M, Hellenbrand W . A multi-country evaluation of Neisseria meningitidis serogroup B factor H-binding proteins and implications for vaccine coverage in different age groups. Pediatr Infect Dis J. 2013; 32(10):1096-101. DOI: 10.1097/INF.0b013e31829aa63b. View

19.

Borrow R, Carlone G, Rosenstein N, Blake M, Feavers I, Martin D . Neisseria meningitidis group B correlates of protection and assay standardization--international meeting report Emory University, Atlanta, Georgia, United States, 16-17 March 2005. Vaccine. 2006; 24(24):5093-107. DOI: 10.1016/j.vaccine.2006.03.091. View

20.

Borrow R, Balmer P, Miller E . Meningococcal surrogates of protection--serum bactericidal antibody activity. Vaccine. 2005; 23(17-18):2222-7. DOI: 10.1016/j.vaccine.2005.01.051. View